Phase 3 Lymphoma Trial, Recruiting NCT07402876 Sponsor: Aldeyra Therapeutics, Inc. Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT07402876
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 21 years or older, of any gender
  • People who have been diagnosed with primary vitreoretinal lymphoma (a type of eye cancer) confirmed through a biopsy
  • People who have lymphoma cells present in the gel-like fluid inside the eye at the time of screening, or who have had eye surgery to remove that fluid as part of confirming their diagnosis
  • People who are willing to take part in the trial and have signed a consent form agreeing to participate

Who may not be able to join:

  • People with a known allergy or sensitivity to a medication called methotrexate
  • People who have eye surgery planned during the period of the trial
  • Women who are pregnant or breastfeeding, or who could become pregnant
  • People with existing eye or other health conditions that, in the trial doctor's opinion, could affect how the trial is run or how the results are interpreted (confirm with trial site)
  • People who have taken methotrexate as a whole-body (systemic) treatment within one week before starting the trial treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 781-257-3063

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Aldeyra Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
1 February 2026
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of clearance of lymphomatous vitreous cells compared across ICM and monthly ADX-2191 treatment groups after eight weeks of treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov